Cadila will benefit from g-Sovaldi

Cadila Healthcare launches g-Sovaldi; however, we are yet to factor in our earnings model; maintain BUY with TP of Rs1,767 | Zydus Cadila (CDH IN) launches Gilead’s Hepatitis C drug - Sofosbuvir in India under the brand – SoviHep. Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi. The drug would be marketed by the speciality division of the group, Zydus Heptiza. (IndiaNivesh)